ArticleFrontiers in cardiovascular medicine2025
Effects of angiotensin receptor-neprilysin inhibition on myocardial energy metabolism and prognosis in patients with acute myocardial infarction complicated by heart failure.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The roles of quantitative doppler echocardiography in optimizing guideline-directed medical therapy in Post-STEMI patients.The international journal of cardiovascular imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the effects of angiotensin receptor-neprilysin inhibitor (ARNI) on myocardial energy metabolism and prognosis in patients with acute myocardial infarction (AMI) complicated by heart failure (HF). Methods: A retrospective analysis was conducted on data from 244 inpatients admitted to our center, who were diagnosed with AMI complicated by HF. Among these patients, 210 completed a 1-year follow-up. According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%). The main outcome measures were the changes in myocardial energy expenditure (MEE) and prognostic indicators after 1-year follow-up. Results: ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61 ± 40.81) kcal/min vs. (154.49 ± 47.58) kcal/min, Conclusion: ARNI significantly reduced MEE compared with ACEI/ARB. MEE was significantly associated with the severity of left ventricular systolic dysfunction and long-term prognosis. An MEE value over 178 kcal/min was a powerful predictor of cardiac death and linked with increased risk of 1-year all-cause mortality in patients with AMI complicated by HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.